Panbela Therapeutics EV/EBITDA
What is the EV/EBITDA of Panbela Therapeutics?
The EV/EBITDA of Panbela Therapeutics Inc. is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on NASDAQ compared to Panbela Therapeutics
What does Panbela Therapeutics do?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Companies with ev/ebitda similar to Panbela Therapeutics
- Guild Esports Plc has EV/EBITDA of N/A
- Delta Drone SA has EV/EBITDA of N/A
- Canaccord Genuity has EV/EBITDA of N/A
- Lordstown Motors has EV/EBITDA of N/A
- Tesla Exploration has EV/EBITDA of N/A
- DigiCrypts Blockchain Solutions has EV/EBITDA of N/A
- Panbela Therapeutics has EV/EBITDA of N/A
- Hapbee Technologies has EV/EBITDA of N/A
- China Parenting Network has EV/EBITDA of N/A
- X4 Pharmaceuticals has EV/EBITDA of N/A
- Delta Drone SA has EV/EBITDA of N/A
- Diablo Resources Ltd has EV/EBITDA of N/A
- cbdMD Inc has EV/EBITDA of N/A